Vancouver-based Aspect Biosystems and Danish pharmaceutical giant Novo Nordisk are expanding their partnership to advance the development of next-generation cellular medicines aimed at treating diabetes.
The companies said the new phase of their collaboration builds on work underway since 2023 and reflects a shared goal of accelerating potentially curative therapies for serious metabolic diseases. Under the updated agreement, Aspect has acquired rights to Novo Nordisk’s stem cell–derived islet cell and hypoimmune cell engineering technologies and will take the lead on development, manufacturing, and commercialization.
Novo Nordisk will retain defined options to expand its role in later-stage development and commercialization. The agreement also includes an additional equity investment by Novo Nordisk in Aspect, along with continued research funding. Novo Nordisk will be eligible for milestone payments and royalties tied to future product sales.
Aspect Biosystems is a member of the BC Tech Association.
BC Tech is the largest member-led technology non-profit in British Columbia, and we’re dedicated to turning startups and scaleups into the anchor companies of tomorrow. Our work supports members to grow and diversify their talent pool, acquire new customers, access capital and accelerate their scaleup journey. Technology is a key industry for BC’s future and builds resiliency in every industry. Today, every company is a tech company. Join now.
As part of the arrangement, select cell therapy research, development, and manufacturing capabilities from Novo Nordisk’s operations in the United States and Denmark will be integrated into Aspect’s Canada-anchored platform. The companies say this will strengthen Aspect’s end-to-end capabilities while expanding access to specialized global talent.
Aspect is applying its platform to develop a new class of cellular medicines targeting metabolic and endocrine diseases, including an islet replacement therapy for type 1 diabetes. The therapy is designed to restore blood glucose control without the need for chronic immune suppression and is based on allogeneic, off-the-shelf cells to support scalable manufacturing.
The expanded partnership positions Aspect to accelerate its push toward clinical development, while giving Novo Nordisk continued exposure to emerging cell therapy technologies aligned with its long-standing focus on diabetes care.
Leave a Reply